Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
Medicines shouldn’t be a luxury Take action
Get involved
Our campaigns

More affordable pneumonia vaccine can protect more kids

Facts about pneumonia vaccine - January 2020
Facts about pneumonia vaccine - January 2020
Facts about pneumonia vaccine - January 2020
Facts about pneumonia vaccine - January 2020

Read, watch, share

3 Questions: How MSF Brought Down the Price of the Pneumonia Vaccine
Video
Video |
06 December 2017
Vaccines

How MSF (and over 400K of you) brought down the price of the pneumonia vaccine

2013 marked the first time that PCV is being used in South Sudan and one of the first vaccines to be implemented in compliance with the new WHO emergency vaccination recommendations. Photograph by Yann Libessart
Press release
Press release |
20 November 2017
Vaccines
India

MSF: India’s decision to give Pfizer unmerited patent on lifesaving pneumonia vaccine limits access for children globally

3 min
Pfizer PCV patent challenge - Advocacy message 9 Nov 17
Video
Video |
09 November 2017
Vaccines

Pfizer PCV patent challenge - Advocacy message

MSF staff prepares a dose of an experimental vaccine Photograph by Yann Libessart
Opinion article
Opinion article |
20 October 2017
Intellectual property and trade
ASEAN

Korea must do its part for global access to affordable medicines and vaccines

5 min
Mothers with young children wait for consultation at the MåSF mobile clinic in Pusuguppa, which is a small village in AP along with border of Chhattisgarh. MSF mobile clinic provides free primary health care services which include diagnostic tests, vaccination, malaria and tuberculosis treatment, antenatal and postnatal consultations. Photograph by Sami Siva Photograph by Sami Siva
Press release
Press release |
13 October 2017
Vaccines
India

MSF approaches Delhi High Court to challenge unmerited patent grant for pneumonia vaccine

fair-shot-vaccine-affordability
Report
Report |
22 September 2017
Vaccines

A Fair Shot for Vaccine Affordability

In New York, on Word Pneumonia Day 2015 (Nov 12), MSF volunteers attempted to deliver more than $17 million of fake cash - the equivalent of one day of profits from the pneumonia vaccines for Pfizer globally -  to Pfizer's CEO Ian Read. The same day, MSF launched a global petition to ask Pfizer and GlaxoSmithKline (GSK) to reduce the price of the pneumococcal vaccine to $5 dollars per child (for all three doses) in developing countries. Credit: Edwin Torres. Photograph by Edwin Torres
Press release
Press release |
27 April 2017
Vaccines

Investors join MSF in calling Pfizer to reduce the price of vaccine against top childhood killer

Sudanese refugees began streaming across the border into South Sudan in June 2011 when conflict erupted between the Khartoum government and the rebels of the Sudan People’s Liberation Movement-North (SPLM-N) in Sudan’s South Kordofan State. At the height of the crisis in Yida camp last summer, high mortality rates were reported among young children admitted to MSF’s hospital with respiratory tract infections, such as pneumonia, one of the leading causes of death. Photograph by Yann Libessart Photograph by Yann Libessart
Feature story
Feature story |
31 January 2017
Vaccines

Pneumonia: “What haunts me is knowing how different it can be for each child, depending on where he or she lives”

6 min
  • Load More
Navigate
  • About MSF Access
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search
Get updates
  • Sign up for our newsletter
  • Privacy & data protection information
Contact

MSF Access
Médecins Sans Frontières
140 Route de Ferney
1202 Geneva, Switzerland
Phone:+41 22 849 8484
E-mail: [email protected]

Follow us

  • X
  • Facebook
  • YouTube
  • Medium
Medicines Shouldn't Be A Luxury